Neuroendocrine Expression in Node Positive Prostate Cancer: Correlation With Systemic Progression and Patient Survival
2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês
10.1016/s0022-5347(05)64626-5
ISSN1527-3792
AutoresDavid G. Bostwick, Junqi Qian, Anna Pacelli, Horst Zincke, Michael L. Blute, Erik J. Bergstralh, Jeffrey M. Slezak, Liang Cheng,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoNo AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Sep 2002Neuroendocrine Expression in Node Positive Prostate Cancer: Correlation With Systemic Progression and Patient Survival David G. Bostwick, Junqi Qian, Anna Pacelli, Horst Zincke, Michael Blute, Erik J. Bergstralh, Jeffrey M. Slezak, and Liang Cheng David G. BostwickDavid G. Bostwick , Junqi QianJunqi Qian , Anna PacelliAnna Pacelli , Horst ZinckeHorst Zincke , Michael BluteMichael Blute , Erik J. BergstralhErik J. Bergstralh , Jeffrey M. SlezakJeffrey M. Slezak , and Liang ChengLiang Cheng View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64626-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Neuroendocrine cells are ubiquitous but uncommon in benign and neoplastic prostate epithelium, and they are considered important for regulating cell growth and differentiation. The predictive value of neuroendocrine immunoreactivity for patient outcome after radical prostatectomy is uncertain. In this study we determined the expression of 2 important neuroendocrine markers, chromogranin and serotonin, in benign epithelium, primary prostate cancer and lymph node metastases, and correlated cellular expression with patient outcome. Materials and Methods: We studied 196 patients with node positive prostate adenocarcinoma who underwent bilateral pelvic lymphadenectomy and radical prostatectomy at Mayo Clinic between 1987 and 1992. Mean followup was 6.8 years (range 0.3 to 11). The cellular expression of chromogranin and serotonin in matched samples of benign tissue, primary prostate cancer and lymph node metastases from the same patients was evaluated by immunohistochemical staining using commercially available monoclonal antibodies. Results were correlated with patient age, pathological findings (Gleason score, DNA ploidy and cancer volume) and patient outcome, including clinical progression, cancer specific and all cause survival. Results: Chromogranin immunoreactivity was greater in benign prostatic epithelium and primary cancer cases (99% each) than in those of lymph node metastases (37.5%) (pairwise comparisons with metastases p <0.001). The mean incidence of immunoreactive cells in benign epithelium, primary cancer and metastases was 6% (median 5%), 6% (median 3%) and 2.2% (median 0%), respectively. Serotonin immunoreactivity was greatest in benign prostate epithelium cases (98.5%) with less in primary cancer (95%) and lymph node metastases (21.5%) (pairwise comparisons p <0.001). The mean incidence of immunoreactive cells in benign epithelium, primary cancer and metastases was 2.2% (median 3%), 2.4% (median 2%) and 0.4% (median 0%), respectively. Chromogranin expression was invariably greater than that of serotonin for all 3 diagnostic categories (p 0.1). No significant association was observed of chromogranin expression in primary cancer or lymph node metastases with any patient outcomes (p >0.1). There was a significant association of the level of serotonin expression in benign prostatic epithelium with cancer specific survival (p = 0.03) but no significant association with systemic progression or all cause survival (p > 0.1). There were positive trends in the association of serotonin immunoreactivity in primary cancer with systemic progression (p = 0.09) and cancer specific survival (p = 0.05) but not with all cause survival (p >0.1). No significant association was observed of serotonin expression in lymph node metastases with any patient outcomes (p >0.1). Conclusions: Benign prostatic epithelium and primary prostate cancer express a significantly greater number of chromogranin and serotonin immunoreactive cells than lymph node metastases, suggesting that decreased expression of neuroendocrine markers is involved in cancer progression. However, neuroendocrine expression was marginally useful for predicting the outcome in patients with node positive prostate cancer treated with radical prostatectomy. References 1 : Peptide-hormone- serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract1987; 182: 298. Crossref, Medline, Google Scholar 2 : The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker.". Pathol Res Pract1989; 185: 373. Crossref, Medline, Google Scholar 3 : Human prostatic endocrine-paracrine (APUD) cells: distributional analysis with a comparison of serotonin neuron-specific enolase immunoreactivity silver stains. Arch Pathol Lab Med1985; 109: 607. Medline, Google Scholar 4 : Endocrine-paracrine cells of the prostate prostatic urethra: an ultrastructural study. Hum Pathol1984; 15: 1034. Crossref, Medline, Google Scholar 5 : Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol1994; 25: 135. Crossref, Medline, Google Scholar 6 : Neuroendocrine differentiation in prostatic intraepithelial neoplasia adenocarcinoma. Am J Surg Pathol1994; 18: 1240. Crossref, Medline, Google Scholar 7 : Prostate cancer neuroendocrine differentiation. Int Urol Nephrol1999; 31: 75. Crossref, Medline, Google Scholar 8 : Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, therapeutic implications. Cancer1992; 70: 254. Crossref, Medline, Google Scholar 9 : Characterization of neuroendocrine differentiation in human benign prostate prostatic adenocarcinoma. Cancer1993; 71: 3952. Crossref, Medline, Google Scholar 10 : Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- post-treatment specimens. Br J Cancer1993; 68: 380. Crossref, Medline, Google Scholar 11 : Cathepsin D chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer1997; 80: 2109. Crossref, Medline, Google Scholar 12 : Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol1998; 160: 406. Link, Google Scholar 13 : Prostatic carcinoma: histological immunohistological factors affecting prognosis. Br J Urol1990; 66: 405. Crossref, Medline, Google Scholar 14 : Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy its clinical significance. Cytometry1985; 6: 327. Crossref, Medline, Google Scholar 15 : Evaluating radical prostatectomy specimens: therapeutic prognostic importance. Virchows Arch1997; 430: 1. Crossref, Medline, Google Scholar 16 : Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?. Br J Urol1995; 75: 751. Crossref, Medline, Google Scholar 17 : The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer1995; 62: 252. Crossref, Medline, Google Scholar 18 : Neuroendocrine stains proliferative indices of prostatic adenocarcinomas in transurethral resection samples. Br J Urol1997; 80: 281. Crossref, Medline, Google Scholar 19 : Neuroendocrine differentiation prognosis in prostatic adenocarcinoma. Br J Urol1997; 80: 287. Crossref, Medline, Google Scholar 20 : Chromogranin A B secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated treated with androgen deprivation therapy. Prostate1998; 34: 113. Crossref, Medline, Google Scholar 21 : Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol1999; 17: 222. Medline, Google Scholar 22 : Neuroendocrine differentiation in prostatic adenocarcinoma its relationship to tumor progression. Cancer1994; 74: 1899. Crossref, Medline, Google Scholar 23 : Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol1996; 27: 683. Crossref, Medline, Google Scholar 24 : The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol1997; 158: 171. Link, Google Scholar 25 : Neuroendocrine differentiation in prostatic adenocarcinoma is not an independent prognostic indicator. Mod Pathol1992; 5: 61A. Medline, Google Scholar 26 : Morphological immunohistochemical investigations of the utriculus prostaticus from the fetal period up to adulthood. Prostate1990; 17: 19. Crossref, Medline, Google Scholar 27 : The neuroendocrine prostate: characterization quantitation of calcitonin in the human gland. J Urol1989; 142: 884. Link, Google Scholar 28 : Immunohistochemical localization of the androgen receptor in neuroendocrine cells in human prostatic tissue prostatic carcinoma. Mod Pathol1993; 6: 54A. Google Scholar 29 : Paneth cell-like metaplasia of the prostate gland. Arch Pathol Lab Med1992; 116: 274. Medline, Google Scholar 30 : Paneth cell-like change small cell carcinoma of the prostate. Two divergent forms of prostatic neuroendocrine differentiation. Am J Surg Pathol1992; 16: 1013. Crossref, Medline, Google Scholar From the Bostwick Laboratories, Richmond, and Department of Pathology, University of Virginia, Charlottesville, Virginia, and Departments of Pathology and Laboratory Medicine, and Urology and Section of Biostatistics, Mayo Clinic, and Mayo Foundation, Rochester Minnesota© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Kannan A, Clouston D, Frydenberg M, Ilic D, Karim M, Evans S, Toivanen R, Risbridger G and Taylor R (2021) Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysisBJU International, 10.1111/bju.15647, VOL. 130, NO. 4, (420-433), Online publication date: 1-Oct-2022. Taher A, Jensen C, Yedururi S, Surasi D, Faria S, Bathala T, Mujtaba B, Bhosale P, Wagner-Bartak N and Morani A (2021) Imaging of Neuroendocrine Prostatic CarcinomaCancers, 10.3390/cancers13225765, VOL. 13, NO. 22, (5765) Oey O, Ghaffari M, Li J and Hosseini-Beheshti E (2021) Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practiceCritical Reviews in Oncology/Hematology, 10.1016/j.critrevonc.2021.103495, VOL. 167, (103495), Online publication date: 1-Nov-2021. Mankuzhy N, Almahariq M, Ye H, Amin M, Stone B and Krauss D (2020) Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive RadiotherapyAmerican Journal of Clinical Pathology, 10.1093/ajcp/aqaa199, VOL. 155, NO. 6, (879-886), Online publication date: 18-May-2021. Balakrishna P, George S, Hatoum H and Mukherjee S (2021) Serotonin Pathway in CancerInternational Journal of Molecular Sciences, 10.3390/ijms22031268, VOL. 22, NO. 3, (1268) Vellky J and Ricke W (2020) Development and prevalence of castration-resistant prostate cancer subtypesNeoplasia, 10.1016/j.neo.2020.09.002, VOL. 22, NO. 11, (566-575), Online publication date: 1-Nov-2020. Kaur H, Samarska I, Lu J, Faisal F, Maughan B, Murali S, Asrani K, Alshalalfa M, Antonarakis E, Epstein J, Joshu C, Schaeffer E, Mosquera J and Lotan T (2020) Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significanceThe Prostate, 10.1002/pros.24035, VOL. 80, NO. 12, (1012-1023), Online publication date: 1-Sep-2020. Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, Röhrich M, Kopka K, Hohenfellner M, Giesel F, Haberkorn U and Kratochwil C (2019) Response Prediction of 177 Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase Journal of Nuclear Medicine, 10.2967/jnumed.119.231431, VOL. 61, NO. 5, (689-695), Online publication date: 1-May-2020. Russell D and Mignano S (2020) Diffuse Synaptophysin Expression in Aggressive Recurrent Castration-Resistant Acinar (Usual) Prostate Cancer: Case Report and Review of Prostatic Neuroendocrine TumorsAJSP: Reviews and Reports, 10.1097/PCR.0000000000000354, VOL. 25, NO. 3, (114-122), Online publication date: 1-May-2020. Bostwick D and Cheng L (2020) Neoplasms of the Prostate Urologic Surgical Pathology, 10.1016/B978-0-323-54941-7.00009-8, (415-525.e42), . Bostwick D (2020) Nonneoplastic Diseases of the Prostate Urologic Surgical Pathology, 10.1016/B978-0-323-54941-7.00008-6, (358-414.e13), . Wang J, Xu W, Mierxiati A, Huang Y, Wei Y, Lin G, Dai B, Freedland S, Qin X, Zhu Y and Ye D (2019) Low‐serum prostate‐specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancerThe Prostate, 10.1002/pros.23878 Fararjeh A and Liu Y (2019) ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate CancerInternational Journal of Molecular Sciences, 10.3390/ijms20112802, VOL. 20, NO. 11, (2802) Tsaur I, Heidegger I, Kretschmer A, Borgmann H, Gandaglia G, Briganti A, de Visschere P, Mathieu R, Valerio M, van den Bergh R, Ost P, Mirvald C, Tilki D, Ploussard G and Surcel C (2019) Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?Cancer Treatment Reviews, 10.1016/j.ctrv.2019.03.001, VOL. 75, (20-26), Online publication date: 1-May-2019. Kardoust Parizi M, Iwata T, Kimura S, Janisch F, Abufaraj M, Karakiewicz P, Enikeev D, Rapoport L, Hutterer G and Shariat S (2019) Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-AnalysisInternational Journal of Molecular Sciences, 10.3390/ijms20061374, VOL. 20, NO. 6, (1374) Bellur S, Van der Kwast T and Mete O (2019) Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinomaHuman Pathology, 10.1016/j.humpath.2018.11.016, VOL. 85, (313-327), Online publication date: 1-Mar-2019. Tomono A, Suzuki S, Yamamoto M, Otowa Y, Kanaji S, Kanemitsu K, Yamashita K, Imanishi T, Sumi Y, Nakamura T, Tanaka K and Kakeji Y (2018) Analysis of Gastric Carcinoma With Neuroendocrine CharacterInternational Surgery, 10.9738/INTSURG-D-15-00062.1, VOL. 103, NO. 11-12, (600-604), Online publication date: 1-Nov-2018. Montironi R, Gasparrini S, Cimadamore A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Briganti A and Scarpelli M (2017) Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of ViewEuropean Urology Supplements, 10.1016/j.eursup.2017.08.010, VOL. 16, NO. 12, (223-231), Online publication date: 1-Dec-2017. Genitsch V, Zlobec I, Seiler R, Thalmann G and Fleischmann A (2017) Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary TumorsInternational Journal of Molecular Sciences, 10.3390/ijms18081640, VOL. 18, NO. 8, (1640) Okeyo-Owuor T, Benesh E, Bibbey S, Reid M, Halabi J, Sutcliffe S, Moley K and Singh S (2017) Exposure to maternal obesogenic diet worsens some but not all pre-cancer phenotypes in a murine genetic model of prostate cancerPLOS ONE, 10.1371/journal.pone.0175764, VOL. 12, NO. 5, (e0175764) Surcel C, van Oort I, Sooriakumaran P, Briganti A, De Visschere P, Fütterer J, Ghadjar P, Isbarn H, Ost P, van den Bergh R, Yossepowitch O, Giannarini G and Ploussard G (2015) Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical reviewUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2014.08.007, VOL. 33, NO. 6, (265.e1-265.e7), Online publication date: 1-Jun-2015. Santoni M, Conti A, Burattini L, Berardi R, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S and Montironi R (2014) Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectivesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 10.1016/j.bbcan.2014.10.008, VOL. 1846, NO. 2, (630-637), Online publication date: 1-Dec-2014. Krauss D, Amin M, Stone B, Ye H, Hayek S, Cotant M, Hafron J and Brabbins D (2013) Chromogranin a staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapyThe Prostate, 10.1002/pros.22771, VOL. 74, NO. 5, (520-527), Online publication date: 1-May-2014. Ciudin A, Huguet Perez J, Ribal Caparros M and Alcaraz Asensio A (2013) Síndrome de Cushing y recidiva de un cáncer de próstata con antígeno prostático específico indetectableMedicina Clínica, 10.1016/j.medcli.2012.09.023, VOL. 140, NO. 9, (430-431), Online publication date: 1-May-2013. Patel S, Molinolo A, Gutkind S, Crawford N and Agoulnik I (2013) Germline Genetic Variation Modulates Tumor Progression and Metastasis in a Mouse Model of Neuroendocrine Prostate CarcinomaPLoS ONE, 10.1371/journal.pone.0061848, VOL. 8, NO. 4, (e61848) Franco R, Chieffi P, Perdonà S, Facchini G and Caraglia M (2013) Neuroendocrine Differentiation in Prostate Cancer Prostate Cancer: Shifting from Morphology to Biology, 10.1007/978-94-007-7149-9_5, (87-109), . Smith B and Odero-Marah V (2014) The role of Snail in prostate cancerCell Adhesion & Migration, 10.4161/cam.21687, VOL. 6, NO. 5, (433-441), Online publication date: 20-Sep-2012. Sagnak L, Topaloglu H, Ozok U and Ersoy H (2011) Prognostic Significance of Neuroendocrine Differentiation in Prostate AdenocarcinomaClinical Genitourinary Cancer, 10.1016/j.clgc.2011.07.003, VOL. 9, NO. 2, (73-80), Online publication date: 1-Dec-2011. Heinrich E, Trojan L, Friedrich D, Voß M, Weiss C, Michel M and Grobholz R (2011) Neuroendocrine tumor cells in prostate cancer: Evaluation of the neurosecretory products serotonin, bombesin, and gastrin - impact on angiogenesis and clinical follow-upThe Prostate, 10.1002/pros.21392, VOL. 71, NO. 16, (1752-1758), Online publication date: 1-Dec-2011. Krauss D, Hayek S, Amin M, Ye H, Kestin L, Zadora S, Vicini F, Cotant M, Brabbins D, Ghilezan M, Gustafson G and Martinez A (2011) Prognostic Significance of Neuroendocrine Differentiation in Patients With Gleason Score 8–10 Prostate Cancer Treated With Primary RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2010.12.064, VOL. 81, NO. 3, (e119-e125), Online publication date: 1-Nov-2011. Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G and Thalmann G (2011) High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early deathVirchows Archiv, 10.1007/s00428-011-1084-z, VOL. 458, NO. 6, (741-748), Online publication date: 1-Jun-2011. Heinrich E, Probst K, Michel M and Trojan L (2010) Gastrin-releasing peptide: Predictor of castration-resistant prostate cancer?The Prostate, 10.1002/pros.21280, VOL. 71, NO. 6, (642-648), Online publication date: 1-May-2011. Netto G and Epstein J (2011) Immunohistology of the Prostate, Bladder, Kidney, and Testis Diagnostic Immunohistochemistry, 10.1016/B978-1-4160-5766-6.00020-0, (593-661), . Bostwick D and Cheng L (2011) Prostate Essentials of Anatomic Pathology, 10.1007/978-1-4419-6043-6_38, (1581-1616), . Ronkainen H, Soini Y, Vaarala M, Kauppila S and Hirvikoski P (2010) Evaluation of neuroendocrine markers in renal cell carcinomaDiagnostic Pathology, 10.1186/1746-1596-5-28, VOL. 5, NO. 1, Online publication date: 1-Dec-2010. McKeithen D, Graham T, Chung L and Odero-Marah V (2010) Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cellsThe Prostate, 10.1002/pros.21132, VOL. 70, NO. 9, (982-992), Online publication date: 15-Jun-2010. Berruti A, Bollito E, Cracco C, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa R and Dogliotti L (2010) The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapyThe Prostate, 10.1002/pros.21104, VOL. 70, NO. 7, (718-726), Online publication date: 15-May-2010. Palapattu G, Wu C, Silvers C, Martin H, Williams K, Salamone L, Bushnell T, Huang L, Yang Q and Huang J (2009) Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancerThe Prostate, 10.1002/pros.20928, VOL. 69, NO. 7, (787-798), Online publication date: 15-May-2009. Vias M, Massie C, East P, Scott H, Warren A, Zhou Z, Nikitin A, Neal D and Mills I (2008) Pro-neural transcription factors as cancer markersBMC Medical Genomics, 10.1186/1755-8794-1-17, VOL. 1, NO. 1, Online publication date: 1-Dec-2008. Jungwirth N, Haeberle L, Schrott K, Wullich B and Krause F (2008) Serotonin used as prognostic marker of urological tumorsWorld Journal of Urology, 10.1007/s00345-008-0285-9, VOL. 26, NO. 5, (499-504), Online publication date: 1-Oct-2008. Frigo D and McDonnell D (2008) Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiationMolecular Cancer Therapeutics, 10.1158/1535-7163.MCT-07-0480, VOL. 7, NO. 3, (659-669), Online publication date: 1-Mar-2008. Palmer J, Venkateswaran V, Fleshner N, Klotz L and Cox M (2008) The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murineLady transgenic prostateThe Prostate, 10.1002/pros.20692, VOL. 68, NO. 4, (345-353), Online publication date: 1-Mar-2008. Park C, Park C, Kim H, Gang K, Song J and Park J (2008) Significance of Neuroendocrine Cell Differentiation in Specimens from Patients with Prostate CancerKorean Journal of Urology, 10.4111/kju.2008.49.7.585, VOL. 49, NO. 7, (585), . Bostwick D and Meiers I (2008) Neoplasms of the prostate Urologic Surgical Pathology, 10.1016/B978-0-323-01970-5.50011-7, (442-579), . Bostwick D, Qian J and Hossain D (2008) Non-neoplastic diseases of the prostate Urologic Surgical Pathology, 10.1016/B978-0-323-01970-5.50010-5, (380-440), . Cindolo L, Franco R, Cantile M, Schiavo G, Liguori G, Chiodini P, Salzano L, Autorino R, Di Blasi A, Falsaperla M, Feudale E, Botti G, Gallo A and Cillo C (2007) NeuroD1 Expression in Human Prostate Cancer: Can It Contribute to Neuroendocrine Differentiation Comprehension?European Urology, 10.1016/j.eururo.2006.11.030, VOL. 52, NO. 5, (1365-1373), Online publication date: 1-Nov-2007. Slovin S (2007) Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behaviorNature Clinical Practice Oncology, 10.1038/ncponc0910, VOL. 4, NO. 9, (551-554), Online publication date: 1-Sep-2007. Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa R and Dogliotti L (2007) Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory DiseaseJournal of Urology, VOL. 178, NO. 3, (838-843), Online publication date: 1-Sep-2007. Martín-Orozco R, Almaraz-Pro C, Rodríguez-Ubreva F, Cortés M, Ropero S, Colomer R, López-Ruiz P and Colás B (2007) EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/AktNeoplasia, 10.1593/neo.07337, VOL. 9, NO. 8, (614-624), Online publication date: 1-Aug-2007. Deeble P, Cox M, Frierson H, Sikes R, Palmer J, Davidson R, Casarez E, Amorino G and Parsons S (2007) Androgen-Independent Growth and Tumorigenesis of Prostate Cancer Cells Are Enhanced by the Presence of PKA-Differentiated Neuroendocrine CellsCancer Research, 10.1158/0008-5472.CAN-06-2616, VOL. 67, NO. 8, (3663-3672), Online publication date: 15-Apr-2007. Schlomm T, Erbersdobler A, Mirlacher M and Sauter G (2007) Molecular staging of prostate cancer in the year 2007World Journal of Urology, 10.1007/s00345-007-0153-z, VOL. 25, NO. 1, (19-30), Online publication date: 15-Mar-2007. Yamada Y, Nakamura K, Aoki S, Taki T, Naruse K, Matsubara H, Tobiume M, Zennami K, Katsuda R and Honda N (2007) An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancerBJU International, 10.1111/j.1464-410X.2006.06500.x, VOL. 99, NO. 1, (189-195), Online publication date: 1-Jan-2007. Huang J, Yao J, di Sant'Agnese P, Yang Q, Bourne P and Na Y (2006) Immunohistochemical characterization of neuroendocrine cells in prostate cancerThe Prostate, 10.1002/pros.20434, VOL. 66, NO. 13, (1399-1406), Online publication date: 15-Sep-2006. Shariff A and Ather M (2006) Neuroendocrine differentiation in prostate cancerUrology, 10.1016/j.urology.2006.02.002, VOL. 68, NO. 1, (2-8), Online publication date: 1-Jul-2006. Quek M, Daneshmand S, Rodrigo S, Cai J, Dorff T, Groshen S, Skinner D, Lieskovsky G and Pinski J (2006) Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancerUrology, 10.1016/j.urology.2005.12.009, VOL. 67, NO. 6, (1247-1252), Online publication date: 1-Jun-2006. Rasiah K, Kench J, Gardiner-Garden M, Biankin A, Golovsky D, Brenner P, Kooner R, O'Neill G, Turner J, Delprado W, Lee C, Brown D, Breit S, Grygiel J, Horvath L, Stricker P, Sutherland R and Henshall S (2006) Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor PrognosisCancer Epidemiology, Biomarkers & Prevention, 10.1158/1055-9965.EPI-05-0752, VOL. 15, NO. 4, (711-716), Online publication date: 1-Apr-2006. Diss J, Faulkes D, Walker M, Patel A, Foster C, Budhram-Mahadeo V, Djamgoz M and Latchman D (2005) Brn-3a neuronal transcription factor functional expression in human prostate cancerProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500837, VOL. 9, NO. 1, (83-91), Online publication date: 1-Mar-2006. Slovin S (2006) Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?Nature Clinical Practice Urology, 10.1038/ncpuro0435, VOL. 3, NO. 3, (138-144), Online publication date: 1-Mar-2006. (2006) Immunohistology of the Prostate, Bladder, Testis and Kidney Diagnostic Immunohistochemistry, 10.1016/B978-0-443-06652-8.50020-X, (509-610), . Bostwick D and Cheng L (2006) Prostate Essentials of Anatomic Pathology, 10.1007/978-1-60327-173-8_31, (1219-1246), . Taplin M, George D, Halabi S, Sanford B, Febbo P, Hennessy K, Mihos C, Vogelzang N, Small E and Kantoff P (2005) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyUrology, 10.1016/j.urology.2005.03.040, VOL. 66, NO. 2, (386-391), Online publication date: 1-Aug-2005. Puccetti L, Supuran C, Fasolo P, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo M, Dogliani N, De Giuli P and Fasolis G (2005) Skewing Towards Neuroendocrine Phenotype in High Grade or High Stage Androgen-Responsive Primary Prostate CancerEuropean Urology, 10.1016/j.eururo.2005.03.018, VOL. 48, NO. 2, (215-223), Online publication date: 1-Aug-2005. Kokubo H, Yamada Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A, Saga S, Tsuzuki T and Hara K (2005) Immunohistochemical study of chromogranin A in Stage D2 prostate cancerUrology, 10.1016/j.urology.2005.01.026, VOL. 66, NO. 1, (135-140), Online publication date: 1-Jul-2005. Daneshmand S, Dorff T, Quek M, Cai J, Pike M, Nichols P and Pinski J (2005) Ethnic differences in neuroendocrine cell expression in normal human prostatic tissueUrology, 10.1016/j.urology.2004.11.052, VOL. 65, NO. 5, (1008-1012), Online publication date: 1-May-2005. Shah R, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M, MacVicar G, Varambally S, Harwood J, Bismar T, Kim R, Rubin M and Pienta K (2004) Androgen-Independent Prostate Cancer Is a Heterogeneous Group of DiseasesCancer Research, 10.1158/0008-5472.CAN-04-2442, VOL. 64, NO. 24, (9209-9216), Online publication date: 15-Dec-2004. Bostwick D, Burke H, Djakiew D, Euling S, Ho S, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters D and Timms B (2004) Human prostate cancer risk factorsCancer, 10.1002/cncr.20408, VOL. 101, NO. S10, (2371-2490), Online publication date: 15-Nov-2004. Wang Q, Horiatis D and Pinski J (2004) Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferationThe Prostate, 10.1002/pros.20106, VOL. 61, NO. 3, (253-259), Online publication date: 1-Nov-2004. Eren F, Çelikel Ç and Güllüoğlu B (2004) Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53Pathology & Oncology Research, 10.1007/BF02893409, VOL. 10, NO. 1, (47-51), Online publication date: 1-Mar-2004. Levin M (2004) A novel immunohistochemical method for evaluation of antibody specificity and detection of labile targets in biological tissueJournal of Biochemical and Biophysical Methods, 10.1016/S0165-022X(03)00149-0, VOL. 58, NO. 1, (85-96), Online publication date: 1-Jan-2004. Brody J, Kadkol S, Hauer M, Rajaii F, Lee J and Pasternack G (2004) pp32 Reduction Induces Differentiation of TSU-Pr1 CellsThe American Journal of Pathology, 10.1016/S0002-9440(10)63117-3, VOL. 164, NO. 1, (273-283), Online publication date: 1-Jan-2004. Finlay J, Mikolajczyk S, Pribyl T, Wallace R and Rittenhouse H (2004) Prostate Cancer Markers Cancer Diagnostics, 10.1007/978-1-59259-791-8_7, (85-128), . Albrecht M, Doroszewicz J, Gillen S, Gomes I, Wilhelm B, Stief T and Aumüller G (2003) Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1β with IL-1β acting as a modulator of cellular differentiationThe Prostate, 10.1002/pros.10288, VOL. 58, NO. 1, (82-94), Online publication date: 1-Jan-2004. Nagakawa O, Fujiuchi Y, Fuse H and Saiki I (2003) Differential effect of chromogranin A fragments on invasion and growth of prostate cancer cells in vitroUrology, 10.1016/S0090-4295(03)00377-7, VOL. 62, NO. 3, (553-558), Online publication date: 1-Sep-2003. Volume 168Issue 3September 2002Page: 1204-1211 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsprostateprostatic neoplasmsneoplasm metastasistumor markers, biologicalneuroendocrine tumorsMetrics Author Information David G. Bostwick More articles by this author Junqi Qian More articles by this author Anna Pacelli More articles by this author Horst Zincke More articles by this author Michael Blute More articles by this author Erik J. Bergstralh More articles by this author Jeffrey M. Slezak More articles by this author Liang Cheng More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)